• Home
  • Search Results
  • Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression.

Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression.

Behavioural brain research (2014-07-22)
Helena Domin, Bernadeta Szewczyk, Monika Woźniak, Anika Wawrzak-Wleciał, Maria Śmiałowska

The glutamatergic predominance in the excitatory-inhibitory balance is postulated to be involved in the pathogenesis of depression. Such imbalance may be induced by astrocyte ablation which reduces glutamate uptake and increases glutamate level in the synaptic cleft. In the present study, we tried to ascertain whether astroglial degeneration in the prefrontal cortex could serve as an animal model of depression and whether inhibition of glutamatergic transmission by the mGluR5 antagonist MTEP could have antidepressant potential. Astrocytic toxins l-or dl-alpha-aminoadipic acid (AAA), 100μg/2μl, were microinjected, bilaterally into the rat medial prefrontal cortex (PFC) on the first and second day of experiment. MTEP (10mg/kg) or imipramine (30mg/kg) were administered on the fifth day. Following administration of MTEP or imipramine the forced swim test (FST) was performed for assessment of depressive-like behavior. The brains were taken out for analysis on day eight. The astrocytic marker, glial fibrillary acidic protein (GFAP) was quantified in PFC by Western blot method and by stereological counting of immunohistochemically stained sections. Both l-AAA and dl-AAA induced a significant increase in immobility time in the FST. This effect was reversed by imipramine, which indicates depressive-like effects of these toxins. A significant decrease in GFAP (about 50%) was found after l-AAA. Both the behavioral and GFAP level changes were prevented by MTEP injection. The obtained results indicate that the degeneration of astrocytes in the PFC by l-AAA may be a useful animal model of depression and suggest antidepressant potential of MTEP.

Product Number
Product Description

Imipramine hydrochloride, ≥99% (TLC)
DL-2-Aminoadipic acid, ≥99%
Imipramine hydrochloride, BioXtra, ≥99% (TLC)
Imipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Imipramine for system suitability, European Pharmacopoeia (EP) Reference Standard
Imipramine hydrochloride, United States Pharmacopeia (USP) Reference Standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.